Zoran Zdraveski
Consigliere Generale presso TSCAN THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 30/04/2024
Posizioni attive di Zoran Zdraveski
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| TSCAN THERAPEUTICS, INC. | Consigliere Generale | 09/09/2021 | - |
| Segretario Aziendale | 09/09/2021 | - |
Storia della carriera di Zoran Zdraveski
Precedenti posizioni note di Zoran Zdraveski
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MAGENTA THERAPEUTICS | Consigliere Generale | 01/04/2017 | 01/04/2021 |
| Segretario Aziendale | 01/03/2018 | 01/04/2021 | |
| EPIZYME, INC. | Corporate Officer/Principal | 01/07/2012 | 01/04/2017 |
Formazione di Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| General Counsel | 2 |
| Corporate Secretary | 2 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Zoran Zdraveski
- Esperienza